checkmate 214 trial update
Published 3 years ago • 195 plays • Length 2:30Download video MP4
Download video MP3
Similar videos
-
1:54
checkmate 214 trial in rcc updates
-
13:10
asco gu24 special: prof. nizar tannir shares checkmate 214 results
-
1:20
renal cell carcinoma: the emulsion and checkmate 214 trials
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
9:00
checkmate 214, keynote-564, and updates in treatment approaches to nccrcc
-
5:06
phase 3 checkmate - 214
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
3:04
success of novel immunotherapies for renal cell carcinoma
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
1:02
key rcc data: javelin renal 101 & checkmate 214
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
4:13
checkmate 214: nivolumab ipilimumab vs sunitinib for advanced or metastatic renal cell carcinoma
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
1:21
dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
-
1:37
dr. amin on rationale for checkmate-214 trial in rcc
-
1:08
laurence albigès, md, phd, shares outcomes & updates from the checkmate 214 study in advanced rcc
-
3:12
analyzing immotion151 data in light of results from checkmate 214 and cabosun trials
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results